UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Volltextzugriff (PDF)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

Annals of oncology, 2016-05, Vol.27 (5), p.868-874

2016

Volltextzugriff (PDF)

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Annals of oncology, 2017-05, Vol.28 (5), p.1090-1097

2017

Volltextzugriff (PDF)

Docetaxel-based combination therapy for castration-resistant prostate cancer

Annals of oncology, 2010-11, Vol.21 (11), p.2135-2144

2010

Volltextzugriff (PDF)

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

BMC cancer, 2021-05, Vol.21 (1), p.593-13, Article 593

2021

Volltextzugriff (PDF)

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Annals of oncology, 2017-03, Vol.28 (3), p.528-534

2017

Volltextzugriff (PDF)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Annals of oncology, 2016-03, Vol.27 (3), p.454-460

2016

Volltextzugriff (PDF)

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of oncology, 2023-03, Vol.34 (3), p.289-299

2023

Volltextzugriff (PDF)

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Annals of oncology, 2020-05, Vol.31 (5), p.626-633

2020

Volltextzugriff (PDF)

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

Annals of oncology, 2005-06, Vol.16 (6), p.923-927

2005

Volltextzugriff (PDF)

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Annals of oncology, 2017-11, Vol.28 (11), p.2754-2760

2017

Volltextzugriff (PDF)

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

Journal of clinical oncology, 1999-08, Vol.17 (8), p.2506-2513

1999

Volltextzugriff (PDF)

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Annals of oncology, 2018-10, Vol.29, p.viii272-viii272

2018

Volltextzugriff (PDF)

Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2509-2516

2001

Volltextzugriff (PDF)

2613 Conditional survival in de novo metastatic urothelial carcinoma: Assessment of 3,410 patients in the SEER database

European journal of cancer (1990), 2015-09, Vol.51, p.S516-S516

2015

Volltextzugriff (PDF)

Impact of Cancer‐Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

The oncologist (Dayton, Ohio), 2000-10, Vol.5 (5), p.353-360

2000

Volltextzugriff (PDF)

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

Annals of oncology, 2018-10, Vol.29, p.viii275-viii276

2018

Volltextzugriff (PDF)

177Lu-PSMA-617 dans le cancer de la prostate métastatique résistant à la castration PSMA positif : analyse des traitements antérieurs et concomitants – VISION

Médecine nucléaire : imagerie fonctionelle et métabolique, 2023-03, Vol.47 (2), p.55-55

2023

Volltextzugriff (PDF)

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Annals of oncology, 2018-10, Vol.29, p.viii320-viii321

2018

Volltextzugriff (PDF)

362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

European journal of cancer (1990), 2015-09, Vol.51, p.S74-S75

2015

Volltextzugriff (PDF)

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii294-viii294

2018

Volltextzugriff (PDF)

Kidney cancer

The Lancet (British edition), 1998-11, Vol.352 (9141), p.1691-1696

1998

Volltextzugriff (PDF)

Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

Chest, 1998-03, Vol.113 (3), p.723-731

1998

Volltextzugriff (PDF)

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

Journal of clinical oncology, 1997-01, Vol.15 (1), p.382-388

1997

Volltextzugriff (PDF)

[177Lu]Lu-PSMA-617 dans le cancer de la prostate métastatique positif au PSMA et résistant à la castration : analyses des sous-groupes de traitement antérieurs et concomitants de l’essai vision

Progrès en urologie. Formation médicale continue, 2022-11, Vol.32 (3), p.S4-S5

2022

Volltextzugriff (PDF)

1 – 25 von 734

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(703)
Mit Volltextzugriff
(606)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(428)
Science & Technology
(424)
Life Sciences & Biomedicine
(420)
Male
(326)
Oncology
(273)
Biological And Medical Sciences
(259)
Medical Sciences
(255)
Middle Aged
(239)
Aged
(222)
Female
(180)
Adult
(172)
Pharmacology. Drug Treatments
(157)
Antineoplastic Agents
(133)
Chemotherapy
(111)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(96)
Aged, 80 And Over
(86)
Prostatic Neoplasms - Drug Therapy
(72)
Urology & Nephrology
(65)
Antineoplastic Agents - Therapeutic Use
(60)
Nephrology. Urinary Tract Diseases
(60)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(176)
Annals Of Oncology
(60)
Cancer
(58)
The Journal Of Urology
(39)
Urology
(26)
Seminars In Oncology
(25)
Clinical Cancer Research
(20)
The New England Journal Of Medicine
(14)
Cancer Chemotherapy And Pharmacology
(13)
Cancer Research
(13)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Docetaxel-based combination therapy for castration-resistant prostate cancer

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

2613 Conditional survival in de novo metastatic urothelial carcinoma: Assessment of 3,410 patients in the SEER database

Impact of Cancer‐Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

177Lu-PSMA-617 dans le cancer de la prostate métastatique résistant à la castration PSMA positif : analyse des traitements antérieurs et concomitants – VISION

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Kidney cancer

Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

[177Lu]Lu-PSMA-617 dans le cancer de la prostate métastatique positif au PSMA et résistant à la castration : analyses des sous-groupes de traitement antérieurs et concomitants de l’essai vision

Suchergebnisse filtern